Skip to main content
Download PDF

Correction: MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer

Molecular Cancer volume 22, Article number: 116 (2023) Cite this article

The Original Article was published on 04 March 2020

FormalPara Correction:

 Mol Cancer 19, 51 (2020)

https://doi.org/10.1186/s12943-020-01174-w

Following publication of the original article [1], the authors identified an error in Fig. 8. In the version of this article initially published, they found one panel in Fig. 8d was used by mistake. The authors want to update it to the correct one. The other elements of the figure remain the same, and the interpretation of the results remains unchanged. The authors’ subsequent studies on MIR22HG have confirmed that the results and conclusions in this study are correct and not affected by this erratum. The correct figure is given below.

Fig. 8
figure 1

MIR22HG increases the CD8 T cells in CRC. a, Scatter plots showing the correlation between CD8A expression and MIR22HG expression. b, Cell-surface expression of PD-L1 and CD8A with overexpressing MIR22HG. Left panels for human cell line and right panels for mouse. c, Relative expression of Cd8a in mice treated with aPD-L1. The right panels showing the IHC staining of CD8A and SMAD2 in tumor and normal tissues of CRC. d, Left panel showing the relative expression of Cd8a in IgG/aPD-L1 + MIR22HG treated mice. Right panel showing the IHC staining of Cd8a. e, The mechanistic scheme of lncRNA MIR22HG in CRC

Full size image

References

  1. Xu J, Shao T, Song M, et al. MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer. Mol Cancer. 2020;19:51. https://doi.org/10.1186/s12943-020-01174-w.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. Juan Xu, Tingting Shao and Mingxu Song contributed equally to this work.

Authors and Affiliations

  1. Key Laboratory of Tropical Translational Medicine of Ministry of Education, College of Biomedical Information and Engineering, Hainan Medical University, Haikou, 571199, China

    Juan Xu & Yongsheng Li

  2. College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, 150081, China

    Juan Xu, Tingting Shao, Yunjin Xie, Jiaqi Yin, Na Ding, Haozhe Zou & Yongsheng Li

  3. Wuxi Oncology Institute, The Affiliated Hospital of Jiangnan University, Wuxi, 214062, China

    Mingxu Song

  4. Department of radiation oncology, The Affiliated Hospital of Jiangnan University, Wuxi, 214062, China

    Jialiang Zhou

  5. The MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Mdicine, Shanghai, 201203, China

    Jiwei Zhang

Authors
  1. Juan Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tingting Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mingxu Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yunjin Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jialiang Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jiaqi Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Na Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Haozhe Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yongsheng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jiwei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Juan Xu, Yongsheng Li or Jiwei Zhang.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at https://doi.org/10.1186/s12943-020-01174-w.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, J., Shao, T., Song, M. et al. Correction: MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer. Mol Cancer 22, 116 (2023). https://doi.org/10.1186/s12943-023-01821-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12943-023-01821-y

Molecular Cancer

ISSN: 1476-4598